Current statistics suggest that someone in the U.S. suffers a stroke every 40 seconds and, given that prevalence increases with advancing age in both males and females [1] , stroke will likely remain as a major cause of death and long-term disability in the coming future. Cell-based therapies aim to improve recovery following ischemic stroke, caused by a lack of blood flow to the brain, via the modulation of the immune system, the secretion of neurogenic and angiogenic factors, and the reduction of infarct volume. Umbilical cord blood (UCB) represents a safe, readily-available, cryopreserved, banked, and immunologically tolerant stem cell-rich product that does not require the invasive collection of autologous cells via bone marrow harvesting or peripheral stem cell collection from already fragile patients [2] . Does UCB also represent a relevant cell source for stroke treatment? This month's first Featured Article from Laskowitz et al. reports the positive results of their phase I safety study of the intravenous (i.v.) infusion of allogeneic UCB as a means to improve functional outcomes in patients with ischemic stroke. In a Related Article, Yang et al. describe how the i.v. infusion of human multipotent adult progenitor cells (MAPCs) immunomodulates splenic responses to generate a more favorable environment for endogenous brain repair after stroke.
FEATURED ARTICLES Phase I Success for Allogeneic Umbilical Cord Blood Infusion for Ischemic Stroke
While stroke represents a major cause of death and long-term disability, we currently lack effective treatment options targeting neuroprotection and promoting recovery. To further explore cell-based therapies for ischemic stroke, the laboratory of Ellen R. Bennett (Duke University, Durham, NC, USA) conducted a Phase I open-label trial to assess the safety and feasibility of a single i.v. infusion of nonhuman leukocyte antigenmatched, unrelated allogeneic hUCB in adult ischemic stroke patients. When compared with bone marrow-derived cells, UCB cells display improved immunotolerance and availability for infusion and may bolster recovery by downregulating inflammation and promoting neuroprotection and plasticity. Encouragingly, Laskowitz et al. report that patients tolerated UCB therapy, did not suffer from any serious adverse events noted, and all participants exhibited improvements in functional outcome by 3 months postinfusion [5] . The authors hope that these results, reported in STEM CELLS Translational Medicine, will support a randomized, placebo-controlled phase II study. 
RELATED ARTICLES Stem Cell Modulation of Systemic Immune Responses Enhances Recovery from Stroke
While stem cells may enhance recovery from stroke in animal models by boosting endogenous repair mechanisms, i.v. injected stem cells can also influence the systemic immune response in the periphery to inhibit or diminish secondary central nervous system damage. To explore this strategy, researchers from the laboratory of Sean I. Savitz (McGovern Medical School at UT-Health, Houston, TX, USA) investigated human MAPC treatment in a male rat model of ischemic stroke [7] . Reporting in STEM CELLS, Yang et al. demonstrate that MAPC therapy enhances stroke recovery in rats with intact spleens by modulating spleen-derived immune responses but displayed no effects in rats without spleens. Further analysis discovered that MAPCs modulated the expression of immune-related genes and reduced pro-inflammatory signaling from the spleen, thereby promoting a pro-regenerative environment for the brain to recover from stroke. DOI: 10.1002/stem.2600
